The epidermal growth factor receptor (EGFR) regulates multiple cellular processes, including proliferation, differentiation, survival, motility, and blood vessel formation. Genetic alterations in the sequence of the EGFR gene or aberrations in the levels of protein expression may result in deregulation of EGFR function. Abnormally active EGFR may become an important contributor to oncogenic processes. The rationale for anti-EGFR therapies in cancer treatment relies on the role that EGFR may play in tumorigenesis and the frequent overexpression or hyperactivation of EGFR noted in many tumor types, including colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), and non-small-cell lung cancer (NSCLC). Overexpression of EGFR correlates with poor outcome and affects all aspects of carcinogenesis, including cell growth and invasion, angiogenesis, and metastasis.[1-4] In addition, the presence of activating mutations of EGFR may be common in malignant cells and correlates with neoplastic progression.
Although tyrosine kinase inhibitors (TKIs) and monoclonal antibodies both inhibit EGFR signaling, their mechanisms of action fundamentally differ. Monoclonal antibodies bind specifically and with high affinity to the extracellular domain of the EGFR, competitively inhibiting binding of other growth factor ligands, including the epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). Another important mechanism of action is antibody-receptor internalization; the EGFR disappears from the cell surface. This prevents ligand-induced autophosphorylation of the EGFR, interrupting the signaling cascade and leading to inhibition of cell growth, migration and metastases, and angiogenesis and induction of apoptosis.[6,7] Monoclonal antibodies may also activate immunologically mediated mechanisms, including antitumor-dependent cellular cytotoxicity and complement-mediated cytotoxicity, although the contribution of this activity to efficacy has not been conclusively demonstrated. By contrast, TKIs bind to the catalytic domain of the EGFR within the cell to block the activation of downstream effectors. Inhibition by TKIs may be either reversible or irreversible, depending on the type of molecule.
Several phase II/III clinical trials have evaluated anti-EGFR therapy in various treatment settings. This article reviews the clinical activity of the TKIs and monoclonal antibodies in CRC, NSCLC, and SCCHN.
Clinical Experience in Metastatic Colorectal Cancer
The majority of the clinical experience with anti-EGFR therapy in metastatic colorectal cancer has been conducted with the monoclonal antibody cetuximab (Erbitux); see Table 1. Phase II trials have shown activity of cetuximab as a single agent and in combination with both irinotecan (Camptosar)- and oxaliplatin (Eloxatin)-based chemotherapy in previously treated patients with metastatic colorectal cancer.[8,9,11,12] Results of a recent phase II trial also show the feasibility and activity of cetuximab plus bevacizumab (Avastin), with or without irinotecan, in patients with metastatic colorectal cancer who failed irinotecan, oxaliplatin, and fluoropyrimidines.
A large, phase II randomized trial conducted by Cunningham et al showed impressive activity alone or in combination with irinotecan in patients with irinotecan-refractory disease. Enrolled patients had documented progression during or within 3 months following irinotecan-based therapy and immunohistochemical evidence of EGFR expression. Patients randomized to cetuximab plus irinotecan achieved an overall response rate of 23%; those treated with cetuximab alone achieved an overall response rate of 11%. The degree of EGFR expression, the number of prior therapies, and previous treatment with oxaliplatin did not affect the activity of study therapy. Treatment was generally well tolerated; the most commonly reported adverse event was skin toxicity. The incidences of diarrhea and neutropenia with irinotecan plus cetuximab were in the range that would be expected with irinotecan alone.
Importantly, the addition of cetuximab to chemotherapy showed modest response in patients who previously progressed on the same chemotherapy regimen, suggesting that addition of cetuximab may overcome treatment resistance in some patients. Correlation of EGFR expression, as determined by immunohistochemistry, with clinical activity of cetuximab is inconsistent. In clinical trials, the degree of EGFR expression as either percentage of cells staining positive or maximal staining intensity per cell did not correlate with response to cetuximab.[8,11] A retrospective analysis has also demonstrated that the activity of cetuximab is similar in both EGFR-negative and EGFR-positive patients, further highlighting the shortcomings of EGFR expression as a selection criterion. A separate retrospective analysis, however, indicated a correlation between increased EGFR copy number as measured by fluorescence in situ hybridization (FISH) and response to anti-EGFR monoclonal antibodies. Response to cetuximab is not dependent on the presence of EGFR mutations.
Several clinical studies have examined whether cetuximab improves the efficacy of the first-line standard chemotherapy regimens FOLFOX (fluorouracil [5-FU]/leucovorin/oxaliplatin) or FOLFIRI (5-FU/leucovorin/irinotecan) in patients with untreated metastatic colorectal cancer. An international phase II study (ACROBAT) has shown that cetuximab improves treatment outcomes when combined with FOLFOX-4 in colorectal cancer patients with untreated, EGFR-overexpressing stage IV disease. Patients administered this combination achieved an overall response rate of 81%, which compares favorably to the 45% observed for FOLFOX-4 alone in the Intergroup 9741 trial. An additional seven patients experienced stable disease, leading to an overall disease control rate of 98%—the highest reported to date in any clinical trial for advanced, metastatic colorectal cancer. The safety profile was tolerable, as the addition of cetuximab to FOLFOX-4 did not produce increases in diarrhea or neutropenia.
Clinical data also show the addition of cetuximab to FOLFIRI to be a safe and potentially efficacious first-line regimen for metastatic colorectal cancer. The feasibility of this combination was first demonstrated in two early-phase clinical studies that showed that cetuximab plus FOLFIRI is active and tolerable as first-line therapy in patients with EGFR-positive metastatic colorectal cancer.[21,22] In addition to these initial promising results, a second phase II study has also shown efficacy for cetuximab with FOLFIRI in this setting. Patients with untreated, EGFR-positive disease achieved response and disease control rates of 43% and 88%, respectively. The addition of cetuximab did not exacerbate the safety profile of FOLFIRI.
Based on these promising results, clinical studies are ongoing to evaluate cetuximab in combination with FOLFOX or FOLFIRI in previously untreated patients with metastatic colorectal cancer. A phase II trial is ongoing to determine the efficacy of cetuximab in combination with FOLFOX-6 as first-line therapy in this setting. The Cancer and Leukemia Group B (CALGB) is conducting a phase III study to compare the FOLFOX-4 and FOLFIRI regimens with or without cetuximab. A second ongoing phase III study, CRYSTAL, is evaluating the efficacy of cetuximab in combination with FOLFIRI in previously untreated patients with EGFR-overexpressing disease.
Tyrosine Kinase Inhibitors
Results of three phase II trials of TKIs in colorectal cancer are available (Table 1). Fisher and colleagues evaluated FOLFOX-4 plus gefitinib (Iressa) in previously treated or untreated patients with advanced colorectal cancer. Previously untreated patients achieved an overall response rate of 77%; previously treated patients achieved an overall response rate of 29%. Treatment resulted in considerable grade 3/4 toxicities, including diarrhea (54%), neutropenia (52%), and vomiting (22%), which were all reported at higher incidences than typically associated with FOLFOX-4 alone. A smaller phase II trial of 5-FU/leucovorin/irinotecan plus gefitinib in previously treated patients with advanced colorectal cancer showed minimal activity, with dose-limiting neutropenia and dehydration/metabolic abnormalities. A trial of single-agent erlotinib (Tarceva) in advanced colorectal cancer patients previously treated with irinotecan or 5-FU reported no objective responses.
Dr. Chu has acted as a consultant for and received research support from Roche, Sanofi, Pfizer, Bristol-Myers Squibb/ImClone, and Genentech.
1. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 94:1593-1611, 2002.
2. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855, 2001.
3. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001.
4. Mendelsohn J: The epidermal growth factor as a target for cancer therapy. Endocr Relat Cancer 8:3-9, 2001.
5. Pedersen MW, Pedersen N, Damstrup L, et al: Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation. J Cell Biochem 96:412-427, 2005.
6. Harris M: Monocloncal antibodies as therapeutic agents for cancer. Lancet Oncol 5:292-302, 2004.
7. Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59(suppl):21-26, 2004.
8. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
9. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004.
10. Saltz LB, Lenz HJ, Hochster H, et al: Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (abstract 169b) [and slide presentation]. Proc Am Soc Clin Oncol GI 2005.
11. Lenz H-J, Mayer RJ, Gold P, et al: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin (abstract 3510). Proc Am Soc Clin Oncol 23:248, 2004.
12. Diaz Rubio E, Tabernero J, van Cutsem E, et al: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study (abstract 3535). J Clin Oncol 23(suppl 16S):254s, 2005.
13. Fisher GA, Kuo T, Cho CD, et al: A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer (abstract 3514) [and slide presentation]. Proc Am Soc Clin Oncol 23:249, 2004.
14. Redlinger M, Kramer A, Flaherty K, et al: A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer (abstract 3767). Proc Am Soc Clin Oncol 23:311, 2004.
15. Townsley C, Major P, Sui LL, et al: Phase II study of OSI-774 in patients with metastatic colorectal cancer (abstract 179). Eur J Cancer 38(suppl 7):S57, 2002.
16. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005.
17. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 6:279-286, 2005.
18. Tsushihashi Z, Khambata-Ford S, Hanna N, et al: Responsiveness to cetuximab without mutations in EGFR [letter]. N Engl J Med 353:208-209, 2005.
19. Tabernero JM, Van Cutsem E, Sastre J, et al: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR): Preliminary results (abstract 3512). Proc Am Soc Clin Oncol 23:248, 2004.
20. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
21. Schoffski P, Lutz MP, Folprecht G, et al: Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR) (abstract 633). Proc Am Soc Clin Oncol 21:159a, 2002.
22. Van Laethem JL, Raoul JL, Mitry E, et al: Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR): Preliminary safety and efficacy results (abstract 1058). Proc Am Soc Clin Oncol 22:264, 2003.
23. Rougier P, Raoul J-L, Van Laethem J-L, et al: Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA (abstract 3513). Proc Am Soc Clin Oncol 23:248, 2004.
24. Scott J, Dakhil S, Cosgriff T, et al: Cetuximab + FOLFOX 6 as first-line therapy for metastatic colorectal cancer (abstract 3705). J Clin Oncol 23(suppl 16S):297s, 2005.
25. Rosell R, Daniel R, Ramlau R, et al: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) (abstract 7012). Proc Am Soc Clin Oncol 23:618, 2004.
26. Thienelt CD, Bunn PA, Hanna N, et al: Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23:8786-8793, 2005.
27. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003.
28. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, and inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149-2158, 2003.
29. Giaccone G, Herbst RS, Manegold C, et al: Getitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784, 2004.
30. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004.
31. Sheperd FA, Pereira JR, Ciuleanu T, et al, for the National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005.
32. Gatzemeier U, Pluzanska A, Szczesna A, et al, for the TALENT Study Investigators: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) (abstract 7010). Proc Am Soc Clin Oncol 23:617, 2004.
33. Herbst RS, Prager D, Hermann R, et al: TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) (abstract 7011). Proc Am Soc Clin Oncol 23:617, 2004.
34. Tsao M-S, Sakurada A, Cutz J-C, et al: Erlotinib in lung cancer-Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005.
35. Kelly DM, Van Schaeybroeck S, Kyula J, et al: EGFR activity determines response of non-small cell lung carcinoma cells to gefitinib (Iressa) in combination with chemotherapy (abstract A118). Presented at the NCI-EORTC-AACR Meeting, November 2005.
36. Ettinger DS, Bepler H, Bueno R, et al: NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 2, 2006. Available at http://www.nccn.org. Last accessed February 17, 2006.
37. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1499, 2004.
38. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
39. Vastag B: For EGFR research, new targeted drugs mean new questions. J Natl Cancer Inst 97:628-630, 2005.
40. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23:5007-5018, 2005.
41. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520, 2005.
42. Dziadziuszko R, Witta S, Cappuzzo F, et al: EGFR mRNA expression detected by RT-PCR predicts sensitivity to gefitinib in advanced non-small cell lung cancer (NSCLC) patients (abstract A257). Presented at the NCI-EORTC-AACR Meeting, November 2005.
43. Hirsch FR, Varella-Garcia M, Bunn PA, et al: Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small cell lung cancer (aNSCLC) treated with gefitinib or placebo (ISEL trial) (abstract A268). Presented at the NCI-EORTC-AACR Meeting, November 2005.
44. Salmon JS, Sandler A, Billheimer D, et al: MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC) (abstract 7022). J Clin Oncol 23(suppl 16S):626s, 2005.
45. Clark GM, Zborowski D, Sandabárbara P, et al: Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression (abstract 7033). J Clin Oncol 23(suppl 16S):628s, 2005.
46. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous cell carcinoma of head and neck. N Engl J Med 354:567-578, 2004.
47. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654, 2005.
48. Trigo J, Hitt R, Koralewski P, et al: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study (abstract 5502) [and slide presentation]. Proc Am Soc Clin Oncol 23:487, 2004.
49. Baselga J, Trigo JM, Bourhis J, et al: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5323-5333, 2005.
50. Herbst RS, Arquette M, Shin DM, et al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578-5587, 2005.
51. Cohen EE, Haraf DJ, Stenson KM, et al: Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC)-A phase II trial (abstract). J Clin Oncol 23(suppl):5506, 2005.
52. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004.
53. Forastiere AA, Ridge JA, Brizel D, et al: NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. Version 1, 2006. Available at http://www.nccn.org. Last accessed February 17, 2006.
54. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998.
55. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003.
56. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998.
57. Jeremic B, Shibamoto Y, Milicic N, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: Aprospective randomized trial. J Clin Oncol 18:1458-1464, 2000.
58. Cohen EE, Rosen F, Stadier WM, et al: Phase I trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003.
59. Cohen EE, Kane MA, List MA, et al: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418-8424, 2005.
60. Cohen EE, Lingen MW, Martin LE, et al: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11:8105-8108, 2005.
61. Kane MA, Cohen E, List M et al: Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN) (abstract 5586). Proc Am Soc Clin Oncol 23:507, 2004.
62. Herbst R, LoRusso PM, Purdom M, et al: Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin Lung Cancer 4:366-369, 2003.
63. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002.
64. Tyagi P: Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 5:21-23, 2005.
65. Malik I, Hecht J, Patnaik A, et al: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 23(suppl):3520, 2005.
66. Weiner LM, Belldegrun A, Rowinsky E, et al: Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol 23(suppl):3059, 2005.
67. Trarbach T, Beyer T, Schleucher N, et al: A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers (abstract 3018). Proc Am Soc Clin Oncol 23:199, 2004.
68. Trarbach T, Schleucher N, Weber D, et al: Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma (abstract 3156). J Clin Oncol 23(suppl 16S):230s, 2005.
69. Rao S, Starling N, Benson M, et al: Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first-line treatment for advanced oesophagogastric (OG) adenocarcinoma (abstract 4028). J Clin Oncol 23(suppl 16S):314s, 2005.
70. Graeven U, Vogel I, Killing B, et al: Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer (abstract 3061). Proc Am Soc Clin Oncol 23:210, 2004.
71. Blohmer J, Gore M, Kuemmel S, et al: Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer (abstract 2534). J Clin Oncol 23(suppl 16S):174s, 2005.